YB-ADC-PDL-1

N/A

Report date: 2022/01/05 15:24:33

Base Information

Drug NameYB-ADC-PDL-1
Drug Alias NameYB-ADC-PDL-1
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAnti-Programmed death-ligand 1
TargetsProgrammed death-ligand 1
Therapy Area/IndicationsMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesHong Kong Medicine Oncolytic Biopharmaceutical (Shenzhen) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHong Kong Medicine Oncolytic Biopharmaceutical (Shenzhen) Co Ltd
Inactive CompaniesN/A
Active IndicationsMelanoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A